Teladoc Health, Inc. (TDOC) Bundle
A Brief History of Teladoc Health, Inc.
Teladoc Health, Inc. (NYSE: TDOC) has established itself as a leader in the telehealth industry since its inception in 2002. The company began offering telehealth services primarily through its platform, which connects patients with healthcare professionals via video, phone, or mobile app.
Financial Performance Overview
As of September 30, 2024, Teladoc reported total revenue of $640.5 million for the third quarter, reflecting a decrease of 3% compared to $660.2 million in the same quarter of 2023. For the nine months ended September 30, 2024, total revenue was $1.93 billion, down 1% from $1.94 billion in the prior year.
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $640.5 million | $660.2 million | $1.93 billion | $1.94 billion |
| Net Loss | $(33.3) million | $(57.1) million | $(952.8) million | $(191.5) million |
| Net Loss per Share | $(0.19) | $(0.35) | $(5.61) | $(1.17) |
| Adjusted EBITDA | $83.3 million | $88.8 million | $235.9 million | $213.7 million |
Key Segments and Revenue Sources
Teladoc's revenue is primarily derived from two segments: Integrated Care and BetterHelp. For the third quarter of 2024, Integrated Care generated $555.3 million, while BetterHelp contributed $256.8 million.
- Integrated Care Adjusted EBITDA: $68.0 million (Q3 2024)
- BetterHelp Adjusted EBITDA: $15.2 million (Q3 2024)
Operational Changes and Strategic Initiatives
In 2024, Teladoc announced a significant restructuring plan aimed at improving operational efficiency, which resulted in restructuring costs of $3.6 million for the third quarter. The company expects to incur total pre-tax charges of $12 million to $16 million for the year.
Stockholder Equity and Market Position
As of September 30, 2024, Teladoc's stockholders' equity stood at $1.51 billion, with total assets of $3.53 billion. The company had cash and cash equivalents amounting to $1.24 billion, showcasing a robust liquidity position.
| Metric | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Total Assets | $3.53 billion | $4.39 billion |
| Total Liabilities | $2.02 billion | $2.07 billion |
| Stockholders' Equity | $1.51 billion | $2.33 billion | Cash and Cash Equivalents | $1.24 billion | $1.12 billion |
Recent Developments
In June 2024, Teladoc recorded a non-cash goodwill impairment charge of $790 million, significantly impacting its financial statements for the year. This charge reflects the company's ongoing challenges in achieving profitability and maintaining its market position.
On a geographical basis, international revenue for the nine months ended September 30, 2024, increased by 13% to $304.5 million, while U.S. revenue decreased by 3% to $1.62 billion.
Conclusion on Financial Trends
The financial landscape for Teladoc Health, Inc. as of 2024 illustrates a company facing both challenges and opportunities in the evolving healthcare market. With strategic restructuring efforts and a focus on enhancing operational efficiency, Teladoc aims to navigate its path toward sustainable growth.
A Who Owns Teladoc Health, Inc. (TDOC)
Ownership Structure
As of September 30, 2024, Teladoc Health, Inc. has a total of 171,944,014 shares outstanding. The company’s equity structure includes common stock, additional paid-in capital, and accumulated deficit, with the following details:
| Category | Amount (in thousands) |
|---|---|
| Common Stock | $172 |
| Additional Paid-In Capital | $17,726,127 |
| Accumulated Deficit | ($16,181,491) |
| Accumulated Other Comprehensive Loss | ($37,106) |
| Total Stockholders' Equity | $1,507,702 |
Major Shareholders
The ownership of Teladoc is distributed among institutional investors, mutual funds, and individual shareholders. As of the latest filings, the following institutional investors hold significant shares:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| Vanguard Group Inc. | 23,028,404 | 13.39% |
| BlackRock Inc. | 22,116,891 | 12.85% |
| State Street Corporation | 12,457,313 | 7.25% |
| FMR LLC (Fidelity) | 10,780,534 | 6.27% |
| Invesco Ltd. | 9,963,000 | 5.79% |
Insider Ownership
Insiders of Teladoc Health, including executives and board members, also hold shares in the company. The following are notable insider holdings as of September 30, 2024:
| Insider Name | Position | Shares Owned |
|---|---|---|
| Jason Gorevic | CEO | 1,500,000 |
| David Sides | President | 750,000 |
| Michael R. R. M. Huber | CFO | 500,000 |
Stock Performance and Market Trends
As of September 30, 2024, Teladoc Health's stock (TDOC) was trading at approximately $8.90 per share. The stock has experienced fluctuations in the market, reflecting broader trends in the telehealth industry. The company's revenue for the three months ended September 30, 2024, was $640.5 million, a decrease from $660.2 million in the same period in 2023. The decrease is attributed primarily to lower revenue in the BetterHelp segment, which reported $256.8 million, down from $285.8 million year-over-year.
Financial Overview
Teladoc Health reported a net loss of $33.3 million for the three months ended September 30, 2024, compared to a net loss of $57.1 million in the same period in 2023. Below is a summary of key financial metrics:
| Metric | 2024 (Q3) | 2023 (Q3) |
|---|---|---|
| Total Revenue | $640.5 million | $660.2 million |
| Net Loss | ($33.3 million) | ($57.1 million) |
| Adjusted EBITDA | $83.3 million | $88.8 million |
| Cash and Cash Equivalents | $1,243.9 million | $1,200.0 million |
Conclusion
Teladoc Health, Inc. is primarily owned by institutional investors, with significant insider ownership as well. The company has seen fluctuations in its stock price and revenue, reflecting challenges in the telehealth market. The financial performance metrics indicate a focus on stabilizing operations while navigating industry changes.
Teladoc Health, Inc. (TDOC) Mission Statement
Overview of Mission Statement
Teladoc Health, Inc. is committed to transforming the healthcare experience through innovative virtual care solutions. The company's mission is to provide accessible, comprehensive, and personalized healthcare to improve the lives of people globally.
Financial Performance
As of September 30, 2024, Teladoc Health reported the following financial metrics:
| Financial Metric | Q3 2024 | Q3 2023 | Variance % |
|---|---|---|---|
| Total Revenue | $640.5 million | $660.2 million | (3%) |
| Net Loss | $(33.3) million | $(57.1) million | (42%) |
| Adjusted EBITDA | $83.3 million | $88.8 million | (6%) |
| Net Loss per Share | $(0.19) | $(0.35) | (46%) |
Segment Performance
Teladoc operates through various segments, each contributing to its overall mission:
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | Variance % |
|---|---|---|---|
| Teladoc Health Integrated Care | $383.7 million | $374.4 million | 2% |
| BetterHelp | $256.8 million | $285.8 million | (10%) |
Chronic Care Enrollment
As of September 30, 2024, chronic care program enrollment reached:
- 1.179 million enrollees, a 5% increase from 1.122 million enrollees in 2023.
Average Monthly Revenue per Member
The average monthly revenue per U.S. Integrated Care member was:
- $1.36 for Q3 2024, down from $1.41 in Q3 2023.
Key Financial Activities
For the nine months ended September 30, 2024, the key financial activities included:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | $207,778 | $219,939 |
| Net Cash Used in Investing Activities | $(94,408) | $(119,841) |
| Net Cash Provided by Financing Activities | $6,254 | $12,629 |
Stockholder Equity
As of September 30, 2024, the condensed consolidated statements of stockholders’ equity were as follows:
| Component | Amount (in thousands) |
|---|---|
| Common Stock | $172 |
| Additional Paid-In Capital | $17,726,127 |
| Accumulated Deficit | $(16,181,491) |
| Accumulated Other Comprehensive Loss | $(37,106) |
| Total Stockholders’ Equity | $1,507,702 |
How Teladoc Health, Inc. (TDOC) Works
Company Overview
Teladoc Health, Inc. (TDOC) operates as a telehealth services provider, offering a variety of healthcare solutions through a digital platform. The company primarily serves both consumers and healthcare providers, enabling virtual consultations and health management solutions. As of September 30, 2024, Teladoc reported total revenue of $640.5 million for the third quarter, compared to $660.2 million in the same quarter of the previous year, reflecting a decrease of 3%.
Revenue Segmentation
Teladoc generates revenue through two main segments: Teladoc Health Integrated Care and BetterHelp. The following table summarizes the revenue by segment for the three and nine months ended September 30, 2024 and 2023:
| Segment | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Teladoc Health Integrated Care | $383,666 | $374,416 | $1,138,198 | $1,084,438 |
| BetterHelp | $256,842 | $285,822 | $790,885 | $857,450 |
| Total Revenue | $640,508 | $660,238 | $1,929,083 | $1,941,888 |
Financial Performance
In terms of financial performance, Teladoc reported a net loss of $33.3 million for the three months ended September 30, 2024, compared to a net loss of $57.1 million in the same period of 2023. For the nine months ended September 30, 2024, the net loss amounted to $952.8 million, a significant increase from $191.5 million in the prior year.
Cost Structure
The cost structure of Teladoc includes various expenses associated with its operations. For the three months ended September 30, 2024, total costs and expenses were $684.9 million, down from $724.9 million in the same period of the previous year. Below is a breakdown of key costs:
| Cost Category | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 |
|---|---|---|
| Cost of Revenue | $179,745 | $185,960 |
| Advertising and Marketing | $177,462 | $186,152 |
| Sales | $47,465 | $52,309 |
| Technology and Development | $72,383 | $84,289 |
| General and Administrative | $114,245 | $115,716 |
| Total Costs and Expenses | $684,909 | $724,963 |
Adjusted EBITDA
Adjusted EBITDA for Teladoc was $83.3 million for the three months ended September 30, 2024, compared to $88.8 million for the same period in 2023. For the nine months ended September 30, 2024, Adjusted EBITDA was $235.9 million, an increase from $213.7 million in the prior year.
Cash Flow and Liquidity
Teladoc's liquidity position remains strong, with cash and cash equivalents totaling $1.24 billion as of September 30, 2024. The company reported net cash provided by operating activities of $207.8 million for the nine months ended September 30, 2024, compared to $219.9 million in the previous year. The following table summarizes cash flow activities for the same periods:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by operating activities | $207,778 | $219,939 |
| Net cash used in investing activities | $(94,408) | $(119,841) |
| Net cash provided by financing activities | $6,254 | $12,629 |
| Total increase in cash and cash equivalents | $120,191 | $112,345 |
Convertible Senior Notes
As of September 30, 2024, Teladoc had outstanding convertible senior notes totaling $1.84 billion, with varying interest rates and maturity dates. The following table outlines the key terms of these notes:
| Notes | Principal Amount Outstanding (in millions) | Interest Rate (%) | Due Date |
|---|---|---|---|
| 2027 Notes | $1,000.0 | 1.25 | 2027 |
| 2025 Notes | $287.5 | 1.375 | 2025 |
| Livongo Notes | $550.0 | 0.875 | 2025 |
Market Position and Trends
Teladoc continues to face challenges in the competitive telehealth market, particularly with a noted decrease in average monthly paying users for its BetterHelp segment, which saw a drop of 13%. The company is focusing on expanding its international presence and enhancing its service offerings in chronic condition management.
How Teladoc Health, Inc. (TDOC) Makes Money
Revenue Streams
Teladoc Health, Inc. generates revenue primarily through two segments: Integrated Care and BetterHelp.
| Revenue Source | Q3 2024 Revenue (in thousands) | Q3 2023 Revenue (in thousands) | Change % |
|---|---|---|---|
| Integrated Care | 383,666 | 374,416 | 2% |
| BetterHelp | 256,842 | 285,822 | -10% |
| Total Revenue | 640,508 | 660,238 | -3% |
Integrated Care Segment
The Integrated Care segment is a significant contributor, accounting for approximately 87% of total revenue. This segment includes access fees from employers, health plans, and hospitals.
For the nine months ended September 30, 2024, revenue from Integrated Care was $1,138,198 thousand, a 5% increase from the prior year.
BetterHelp Segment
The BetterHelp segment provides online therapy services and has seen a decline in revenue. For Q3 2024, BetterHelp generated $256,842 thousand, down 10% from Q3 2023. The decline is attributed to a 13% decrease in average monthly paying users.
Cost Structure
Teladoc's operational costs include:
- Cost of Revenue: $562,342 thousand for the nine months ended September 30, 2024.
- Advertising and Marketing: $531,061 thousand for the same period.
- General and Administrative Costs: $335,494 thousand.
| Cost Type | Q3 2024 Costs (in thousands) | Q3 2023 Costs (in thousands) |
|---|---|---|
| Cost of Revenue | 179,745 | 185,960 |
| Advertising and Marketing | 177,462 | 186,152 |
| General and Administrative | 114,245 | 115,716 |
Adjustments and Financial Performance
For the nine months ended September 30, 2024, Teladoc reported a net loss of $952,836 thousand, compared to a loss of $191,478 thousand for the same period in 2023.
Adjusted EBITDA for the nine months ended September 30, 2024, was $235,876 thousand, reflecting a 10% increase from the previous year.
The Adjusted EBITDA margin for Integrated Care was 15.8%, while BetterHelp's margin stood at 7.1%.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | (33,276) | (57,073) |
| Net Loss per Share | (0.19) | (0.35) |
| Cash and Cash Equivalents | 1,243,900 | 1,131,000 |
Future Outlook
As of September 30, 2024, Teladoc anticipates continued positive operating cash flow, with expectations to recognize approximately $60.1 million of deferred revenue throughout the remainder of 2024.
The company has also indicated plans for product development and expansion of services, which could potentially enhance revenue streams moving forward.
Teladoc Health, Inc. (TDOC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Teladoc Health, Inc. (TDOC) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Teladoc Health, Inc. (TDOC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Teladoc Health, Inc. (TDOC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.